Abstract:Objective:To investigate the effects of tamoxifen on high glucose-induced epithelial-to-mesenchymal transition of rat peritoneal mesothelial cells and the underlying mechanism.Methods:The peritoneal mesothelial cells of normal male SD rats were selected between January 2015 and June 2016 and then cultured and divided into blank control, high-glucose stimulation and drug intervention groups. High-glucose stimulation group: primary cultured rat peritoneal mesothelial cells (RPMCs) were treated with 60 mmol/L high-concentration glucose to induce epithelial-to-mesenchymal transition. Drug intervention group: (1) RPMCs were treated with 60 mmol/L high-concentration glucose and different concentrations (0.5 μmol/L, 2 μmol/L) of tamoxifen. After 72 hours of stimulation, protein was extracted. (2) RPMCs were treated with 60 mmol/L high-concentration glucose and 2 μmol/L tamoxifen with or without 2 μmol/L ER-α antagonist for 1 hour to extract protein and for 6 hours to extract RNA. (3) RPMCs were treated with high-concentration glucose and 2 μmol/L tamoxifen with or without 1 μmol/L 1 μM proteasome inhibitor for 1 hour to extract protein. Western blot analysis was performed to analyze change in E-cadherin, α-SMA, Smad2, p-Smad2, Smad3, p-Smad3 and Smad4 protein. Real-time fluorescence quantitative PCR was performed to detect the change in mRNA expression of Smad2, Smad3, connective tissue growth factor and plasminogen activator inhibitor 1.Results:Tamoxifen attenuated epithelial-to-mesenchymal transition on RPMCs induced by high-level glucose, showing increased expression of epithelial cell marker E-cadherin and decreased expression of α-SMA in a concentration-dependent manner ( tE-cadherin = 2.31, tα-SMA =-2.53, both P < 0.05).TGF-β1/R-Smad signal pathway was activated by high-concentration glucose. Phosphorylation of Smad2/3 and mRNA expression of CTGF and PAI-1 were increased. Tamoxifen remarkably reduced protein and mRNA level of above mentioned protein and related target genes ( tp-Smad2 = -3.38, tCTGF = -3.81, P < 0.05), which could be blocked by ER-α antagonist. Finally, proteasome inhibitor could weaken the inhibitory effects of tamoxifen on p-Smad2/3 and increase p-Smad2/3 protein level ( tp-Smad2 = 3.94, P < 0.05). Conclusion:Tamoxifen activates ER-α on RPMCs, weakens the activation of TGF-β1/R-Smad signal pathway through decreasing p-Smad2 protein level, and effectively inhibits the progression of high-concentration glucose-induced epithelial-to-mesenchymal transition possibly through degrading p-Smad2 protein through proteasome. The role of tamoxifen in epithelial-to-mesenchymal transition may provide a possible guide for research, prevention and treatment of peritoneal fibrosis.

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Rapamycin Inhibits Peritoneal Fibrosis by Modifying Lipid Homeostasis in the Peritoneum

The mechanism by which tamoxifen attenuates high glucose-induced epithelial-to-mesenchymal transition of rat peritoneal mesothelial cells

Impact of rapamycin on peritoneal fibrosis and transport function.

MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration.

Rapamycin Inhibits Transforming Growth Factor Β-Induced Peritoneal Angiogenesis by Blocking the Secondary Hypoxic Response.

Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of Mtor Signaling in Interstitial Macrophages and Myofibroblasts

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension.

Rapamycin Prevents Endothelial Cell Migration by Inhibiting the Endothelial-To-Mesenchymal Transition and Matrix Metalloproteinase-2 and -9: an in Vitro Study

RhoA/Rho-kinase Triggers Epithelial-Mesenchymal Transition in Mesothelial Cells and Contributes to the Pathogenesis of Dialysis-Related Peritoneal Fibrosis

Rapamycin inhibits mesenteric neo-angiogenesis in portal hypertensive rats

Epithelial–mesenchymal transition of rat peritoneal mesothelial cells via Rhoa/Rock pathway

Comparison of Anti-Peritoneal Fibrotic Effects Between an Mtorc1-Specific Blocker and a PI3K/mTOR Dual-Blocker.

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

Inhibition of PI3K/AKT/mTOR Signalling Pathway Activates Autophagy and Suppresses Peritoneal Fibrosis in the Process of Peritoneal Dialysis

Effect of Rapamycin on TGF-β1-induced Epithelial-Mesenchymal Transition in LoVo Colonic Adenocarcinoma Cells

Inhibition of Mtor Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Regulating Epithelial-Mesenchymal Transition.

Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats Through Inhibition of Mtorc1 but Not Mtorc2.

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity